BetterLife Pharma (BETRF) Research & Development (2011 - 2026)
BetterLife Pharma (BETRF) posted quarterly Research & Development of $15685.8 for Q2 2026, up 63.85% year-over-year from $9573.3 in Q2 2025, and up 1265.83% quarter-over-quarter from $1148.4 in Q3 2025.
BetterLife Pharma (BETRF) Research & Development (2011 - 2026) Analysis & Trends
BetterLife Pharma's Research & Development history runs 11 years deep, the most recent figure standing at $15685.8 for Q2 2026.
- In Q2 2026, Research & Development rose 63.85% year-over-year to $15685.8; the TTM figure through Apr 2026 stood at $48839.3 (down 79.2% YoY), while the FY2026 annual figure was $61732.6, down 79.35% from the prior year.
- Research & Development for Q2 2026 stood at $15685.8, up from $1148.4 in the prior quarter.
- The five-year high for Research & Development was $1.5 million in Q2 2022, with the low at $1148.4 in Q3 2025.
- The 5-year median for Research & Development is $91574.3 (2023), against an average of $210796.6.
- The sharpest annual moves came in 2022 and 2025: Research & Development jumped 448.77% in 2022, then slumped 99.42% in 2025.
- BetterLife Pharma's Research & Development stood at $19479.7 in 2022, then jumped by 405.44% to $98458.4 in 2023, then slumped by 94.51% to $5400.6 in 2024, then plunged by 78.73% to $1148.4 in 2025, then jumped by 1265.83% to $15685.8 in 2026.
- Business Quant data shows BETRF's Research & Development at $15685.8 in Q2 2026, $1148.4 in Q3 2025, and $9573.3 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 413.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 210.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 97.90 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -588.31 Mn |
| 10 | BetterLife Pharma | 40.15 Mn | 42.53 Mn | - | 15,685.84 |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | 15,685.84 |
| Jul 31, 2025 | 1,148.45 |
| Apr 30, 2025 | 9,573.27 |
| Jan 31, 2025 | 22,431.77 |
| Oct 31, 2024 | 5,400.63 |
| Jul 31, 2024 | 197,393.83 |
| Apr 30, 2024 | 84,690.19 |
| Jan 31, 2024 | 137,587.46 |
| Oct 31, 2023 | 98,458.38 |
| Jul 31, 2023 | 138,452.11 |
| Apr 30, 2023 | 49,253.93 |
| Jan 31, 2023 | 318,262.83 |
| Oct 31, 2022 | 19,479.66 |
| Jul 31, 2022 | 238,557.76 |
| Apr 30, 2022 | 1.51 Mn |
| Jan 31, 2022 | 524,118.03 |
| Oct 31, 2021 | 949,250.78 |
| Jul 31, 2021 | 1.82 Mn |
| Apr 30, 2021 | 1.05 Mn |
| Jan 31, 2021 | -150,277.94 |